<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746043</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0117</org_study_id>
    <secondary_id>NCI-2013-00584</secondary_id>
    <secondary_id>R01CA026582</secondary_id>
    <nct_id>NCT01746043</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare armodafinil and minocycline when given
      alone or in combination to learn which is better for controlling side effects of
      chemoradiation treatment for esophageal cancer (such as fatigue, pain, disturbed sleep, lack
      of appetite, and drowsiness).

      Armodafinil is designed to prevent excessive sleepiness.

      Minocycline is an antibiotic, which may help to reduce multiple symptoms.

      In this study, you may receive a placebo. A placebo is not a drug. It looks like the study
      drug but is not designed to treat any disease or illness. It is designed to be compared with
      a study drug to learn if the study drug has any real effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are eligible to take part in this study, you will be randomly assigned (as in the roll
      of dice) to join 1 of 4 groups. You will have an equal chance of being in any group.

        -  Group 1 will take armodafinil and a placebo.

        -  Group 2 will take minocycline and a placebo.

        -  Group 3 will take armodafinil and minocycline.

        -  Group 4 will take 2 placebos.

      Neither you nor the study staff you will see in the clinic will know if you are receiving the
      study drug(s) and/or the placebo(s). However, if needed for your safety, the study staff will
      be able to find out which study drug you are receiving.

      If needed, you will be given standard drugs to help decrease the risk of side effects. You
      may ask the study staff for information about how the drugs are given and their risks.

      Study Drug/Placebo Administration:

      You will take the study drug/placebo 2 times a day for 6 weeks. You should take the capsules
      with a full glass of water. If you get an upset stomach, take them with food.

      You will be given pamphlets with more information about how to take the study capsules.

      You should bring your study capsules to every study visit.

      Completing the Symptom Questionnaire:

      Throughout the study, you will be asked to complete a questionnaire about your symptoms. This
      questionnaire will ask about symptoms from therapy you may be having and how they may be
      interfering with your daily activities. The study staff will either meet you during your
      regular clinic visit or call you at your home at a time that is convenient for you. In the
      clinic, you will complete the questionnaire by paper and pen, or by entering your answers
      into an electronic tablet computer. On the phone, a study staff member will ask you the
      questions and record your answers. You will complete the symptom questionnaire before you
      begin chemoradiation and then 1 time a week for the rest of the study. The symptom
      questionnaire will take up to 5 minutes to complete.

      Study Visits:

      Before you begin chemoradiation:

        -  You will complete questionnaires about pain and other symptoms, your mood, and your
           quality of life. Completing all 5 questionnaires will take about 15 minutes.

        -  If you can become pregnant and you did not have a pregnancy test during screening, you
           will have a urine pregnancy test. The study staff will give you the urine pregnancy test
           kit at your scheduled visit, and will review the results before you pick up the study
           capsules from the pharmacy.

      About Week 3 or 4, you will be asked to complete a questionnaire that asks you about your
      satisfaction with the study capsules. This will take a few minutes.

      During the last week of chemoradiation (about Week 5 or 6):

        -  You will complete 3 questionnaires about your symptoms, mood, and quality of life. These
           questionnaires will take about 10 minutes total to complete.

        -  You will also be asked to complete a questionnaire that asks about your satisfaction
           with the study capsules. This will take a few minutes.

      After about Week 5 or 6, the study staff will call you 1 time a week to check on you until
      the study ends. This phone call should last only a few minutes. If you have had several side
      effects from chemoradiation, this phone call may take longer.

      At your first routine clinical follow-up visit (about Week 10 to 14):

        -  You will complete the 3 questionnaires about your symptoms, mood, and quality of life.

        -  You will also be asked to complete another questionnaire that asks about your
           satisfaction with the study capsules.

      Length of Study:

      You will be on study for about 10-14 weeks. You will take the study drug(s) for 6 weeks and
      complete the symptom survey until the end of the study. You will be taken off study early if
      you have intolerable side effects.

      This is an investigational study. Armodafinil is FDA approved and commercially available for
      the treatment of sleepiness. Minocycline is FDA approved and commercially available for the
      treatment of bacterial infections. The use of these drugs to help reduce chemoradiation
      symptoms is investigational.

      Up to 80 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>Mean symptom score defined as the mean of MDASI fatigue, pain, disturbed sleep, lack of appetite, and drowsiness scores</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Armodafinil</intervention_name>
    <description>150 mg by mouth once a day for 6 weeks.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule by mouth 2 times a day for 6 weeks.</description>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100 mg by mouth 2 times a day for 6 weeks.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <other_name>Dynacin</other_name>
    <other_name>Minocin</other_name>
    <other_name>Minocin PAC</other_name>
    <other_name>Myrac</other_name>
    <other_name>Solodyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.</description>
    <arm_group_label>Armodafinil + Minocycline</arm_group_label>
    <arm_group_label>Armodafinil + Placebo</arm_group_label>
    <arm_group_label>Minocycline + Placebo</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a pathologically proven diagnosis of esophageal cancer

          2. Patients &gt; or = 18 years old

          3. Patients who will receive chemotherapy and radiation therapy

          4. Patients who speak English or Spanish

          5. Patients must be willing and able to review, understand, and provide written consent
             before starting therapy

          6. Patients must agree to discontinue St John's Wort herbal supplement use, and refrain
             from taking it while on protocol

          7. Women of childbearing potential (women who are not postmenopausal for at least 1 year
             and are not surgically sterile) must have a negative urine pregnancy test

          8. Sexually active males and females must agree to use effective birth control or to be
             abstinent for the duration of the study period

          9. Women currently taking birth control pills or planning to start birth control pills
             must agree to an additional method of birth control (either abstinence or a barrier
             method) while on the study medication and for 1 additional month after study
             completion.

        Exclusion Criteria:

          1. Patients who are enrolled in other symptom management clinical trials

          2. Patients currently taking methylphenidate and/or dextroamphetamine

          3. Patients with a history of clinically significant cutaneous drug reaction, or a
             history of clinically significant hypersensitivity reaction, as documented in the
             patient medical records

          4. Patients with pre-existing psychosis or bipolar disorder

          5. Patients with pre-existing renal impairment: The screening cut off for serum
             creatinine &gt;1.5 times the upper limit of normal, within the past 30 days, will be done
             by the oncologist to qualify for CXRT.

          6. Patients with pre-existing hepatic impairment: The screening for total bilirubin &gt;25.7
             Âµmol/L (1.5 mg/dL) will be done by the oncologist to qualify for CXRT. The screening
             for &gt; 2 times the upper limit of normal hepatotoxicity, alkaline phosphatase (ALP),
             and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) will be done by
             the oncologist to qualify for CXRT.

          7. Patients with pre-existing Tourette's syndrome

          8. Patients with hypersensitivity to any tetracyclines

          9. Patients with uncontrolled cardiac disease, including angina and cardiac ischemia,
             left ventricular hypertrophy, myocardial infarction, and mitral valve prolapse.

         10. Patients taking medicines that are strong CYP3A4 inhibitors or inducers (including
             conivaptan, indinavir, nelfinavir, ritonavir, nefazodone, and phenetoin), or strong
             CYP2C19 inhibitors (including citalopram and clopidogrel).

         11. Patients on vitamin K antagonist warfarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H. Lin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>XRT</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>CXRT</keyword>
  <keyword>Symptom Burden</keyword>
  <keyword>Armodafinil</keyword>
  <keyword>Nuvigil</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Dynacin</keyword>
  <keyword>Minocin</keyword>
  <keyword>Minocin PAC</keyword>
  <keyword>Myrac</keyword>
  <keyword>Solodyn</keyword>
  <keyword>Placebo</keyword>
  <keyword>Sugar pill</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: February 25, 2013 to January 5, 2017. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 22 participants enrolled 1 participant were excluded from the study before assignment to groups: Of the 21 randomized patients, 19 (90%) were evaluable for the primary efficacy analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil + Placebo</title>
          <description>Armodafinil 150mg once a day during the entire course of radiation (6 weeks + 5 days).</description>
        </group>
        <group group_id="P2">
          <title>Minocycline + Placebo</title>
          <description>Minocycline 100mg twice a day during the entire course of radiation therapy (6 weeks + 5 days)</description>
        </group>
        <group group_id="P3">
          <title>Armodafinil + Minocycline</title>
          <description>Armodafinil (150 mg once a day for 6 weeks) + Minocycline (100 mg twice a day for 6 weeks).</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil + Placebo</title>
          <description>Armodafinil 150mg once a day during the entire course of radiation (6 weeks + 5 days)</description>
        </group>
        <group group_id="B2">
          <title>Minocycline + Placebo</title>
          <description>Minocycline 100mg twice a day during the entire course of radiation therapy (6 weeks + 5 days)</description>
        </group>
        <group group_id="B3">
          <title>Armodafinil + Minocycline</title>
          <description>Armodafinil (150 mg once a day for 6 weeks) + Minocycline (100 mg twice a day for 6 weeks).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="4.6"/>
                    <measurement group_id="B2" value="64.5" spread="0.6"/>
                    <measurement group_id="B3" value="61.6" spread="10.2"/>
                    <measurement group_id="B4" value="56.2" spread="4.9"/>
                    <measurement group_id="B5" value="61.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.</title>
        <description>Mean symptom score defined as the mean of MDASI fatigue, pain, disturbed sleep, lack of appetite, and drowsiness scores</description>
        <time_frame>Baseline, 6 weeks</time_frame>
        <population>Of the 21 randomized patients , 19 (90% were evaluable for the primary efficacy analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil + Placebo</title>
            <description>Armodafinil 150mg once a day during the entire course of radiation (6 weeks + 5 days)</description>
          </group>
          <group group_id="O2">
            <title>Minocycline + Placebo</title>
            <description>Minocycline 100mg twice a day during the entire course of radiation therapy (6 weeks + 5 days)</description>
          </group>
          <group group_id="O3">
            <title>Armodafinil + Minocycline</title>
            <description>Armodafinil (150mg once a day) + Minocycline (100mg once a day)</description>
          </group>
          <group group_id="O4">
            <title>Placebos</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Under Each Treatment Arm Who Experienced a Mean Symptom Increase of 2 Units or More From Baseline to 6 Weeks.</title>
          <description>Mean symptom score defined as the mean of MDASI fatigue, pain, disturbed sleep, lack of appetite, and drowsiness scores</description>
          <population>Of the 21 randomized patients , 19 (90% were evaluable for the primary efficacy analysis).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil</title>
          <description>Armodafinil 150 mg once a day during the entire course of chemoXRT (6 weeks + 5 days) or a total of 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Minocycline</title>
          <description>Minocycline 100 mg twice a day during the entire course of chemoXT ( 6 weeks + 5 days)</description>
        </group>
        <group group_id="E3">
          <title>Armodafinil+Minocycline</title>
          <description>Armodafinil + Minocycline</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lin,Steven H,M.D. Ph.D. / Radiation Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-7734</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

